Zaharaddeen Umar Na’abba and Abhishek Kumar Verma*
Department of Life Sciences, School of Science and Technology, Mewar University, Gangrar, Chittorgarh Rajasthan, India
*Corresponding Author: Abhishek Kumar Verma, Assistant Professor, Department of Life Sciences, School of Science and Technology, Mewar University, Gangrar, Chittorgarh, Rajasthan, India. E-mail: abhishekbairwa913@gmail.com
Received: July 26, 2020; Published: August 01, 2020
Currently, the FDA for the treatment of COVID-19 pneumonia has approved no drugs or therapeutics vaccines. Some pharmacological treatment has gained emergency use authorization from FDA based on preliminary data displaying a faster time to recovery of hospitalized patients with severe COVID-19 infection. In this editorial, different pharmacological treatment that have been adopted for the management and treatment of COVID-19 pneumonia.
Citation: Zaharaddeen Umar Na’abba and Abhishek Kumar Verma. “Pharmacological Treatments and Development of SARS-CoV-2". Acta Scientific Pharmaceutical Sciences 4.9 (2020): 01-02.
Copyright: © 2020 Zaharaddeen Umar Na’abba and Abhishek Kumar Verma. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Open Access by
Acta Scientific is licensed under a Creative Commons Attribution 4.0 International License
Based on a work at https://actascientific.com
ff
